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Abstract 
Goals of work The aim of this secondary data analysis was to investigate symptom clusters 
over time for symptom management of a patient group after commencing adjuvant 
chemotherapy. 
Materials and methods A prospective longitudinal study of 219 cancer outpatients conducted 
within 1 month of commencing chemotherapy (T1), 6 months (T2), and 12 months (T3) later. 
Patients’ distress levels were assessed for 42 physical symptoms on a clinician-modified 
Rotterdam Symptom Checklist. Symptom clusters were identified in exploratory factor 
analyses at each time. Symptom inclusion in clusters was determined from structure 
coefficients. Symptoms could be associated with multiple clusters. Stability over time was 
determined from symptom cluster composition and the proportion of symptoms in the initial 
symptom clusters replicated at later times.    
Main results Fatigue and daytime sleepiness were the most prevalent distressing symptoms 
over time. The median number of concurrent distressing symptoms approximated 7, over 
time. Five consistent clusters were identified at T1, T2, and T3. An additional two clusters 
were identified at 12 months, possibly due to less variation in distress levels. Weakness and 
fatigue were each associated with 2, 4, and 5 symptom clusters at T1, T2, and T3, 
respectively, potentially suggesting different causal mechanisms.    
Conclusion Stability is a necessary attribute of symptom clusters, but definitional clarification 
is required. We propose a core set of concurrent symptoms identifies each symptom cluster, 
signifying a common cause. Additional related symptoms may be included over time. Further 
longitudinal investigation is required to identify symptom clusters and the underlying causes. 
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Introduction 
The cancer symptom experience has been described as dynamic [1], depending on the type 
and stage of cancer and treatment, although some symptoms are common to most cancers. 
Fatigue is the most frequently reported cancer-related symptom, irrespective of cancer type 
[2-4]. Symptom management strategies depend on understanding the complexity of patients’ 
symptom experiences and the underlying causes. A symptom cluster approach to address the 
multiple symptom experience of cancer patients may lead to new symptom management 
strategies [5,6].  
Symptom clusters have been defined as a stable grouping of at least two related, co-
occurring symptoms [7]. Type and strength of relationships [8] and co-occurrence have not 
been specified. Symptom relatedness is generally shown statistically by correlation, but 
correlated symptoms are not necessarily related physiologically, and there is no sense of 
causality. Stability of symptom clusters is important clinically to develop intervention 
strategies, but has not been defined for this context. Conceptually, stability may refer to 
consistent/replicated symptom clusters for a patient group at a point in time (cross-sectional 
stability) or over time, or in individuals over time, and for different patient populations 
(subgroups).   
Few studies have investigated symptom clusters using longitudinal data, although 
symptoms may persist across disease and treatment trajectories [9,10,3]. The purpose of this 
study was to investigate symptom clusters over time for a patient group, as a basis for 
symptom management.  
 
Literature Review 
For longitudinal data, symptom clusters have been identified for patient groups in 
separate cross-sectional factor analyses. For example, the structure of two symptom clusters 
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(Upper-gastrointestinal, Psychoneurological) was identified in a study of 199 breast cancer 
patients during and after chemotherapy/radiotherapy treatment [11]. Both clusters were 
replicated after treatment, except hot flashes was in the Upper-gastrointestinal cluster during 
treatment. Using a congruence coefficient to determine similarity across patient subgroups 
(e.g., treatment type, early/late stage, gender) during treatment and Cronbach’s alpha for 
internal reliability, cross-sectional stability was demonstrated for both clusters. After 
treatment, only the Upper-gastrointestinal cluster was consistent for all subgroups [11]. 
Subgroup factor analyses would be a preferred method to identify clusters [12], dependent on 
sample size. 
Typically, stability of symptom clusters identified over time has been determined 
qualitatively by noting similar symptom groupings across clusters. For 66 patients newly-
diagnosed with brain tumors, a core set of symptoms was identified consistently in two 
clusters (Language, Mood), before and after 12 weeks of radiotherapy [13]. Similarly, 
consistency was evident in three clusters identified for 160 breast and prostate cancer patients 
at the middle (T1), end (T2), and one month after (T3) radiotherapy [14]. In contrast, 
symptom clusters varied every week (0-12 weeks) after radiotherapy, in studies of 518 
patients with bone metastases [15] and 170 patients with brain metastases [16]. Consistent 
pairs over time were fatigue and drowsiness, and anxiety and depression. In another study of 
129 patients with brain metastases, five symptom pairs were consistent, but in different 
clusters, in three, monthly assessments after whole brain radiotherapy [17].  
Stability/consistency of cancer symptom clusters has also been determined by 
confirmatory factor analysis, but this requires hypotheses of symptom relationships based on 
prior knowledge. In a validation study, Chen and Lin [18] used confirmatory factor analysis, 
and replicated three symptom clusters (sickness, gastrointestinal, and emotional) identified 
previously [19] were replicated [18], despite sample differences in treatments and diagnoses. 
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A model associating lack of appetite with the Gastrointestinal and Sickness clusters was a 
better-fit model, indicating symptoms may result from more than one cluster. Stability of a 
symptom cluster (fatigue, weakness, nausea, vomiting, appetite loss, weight loss, altered 
taste) identified for 112 lung cancer patients at diagnosis was determined three and six 
months later using Cronbach’s alpha [20,21]. Clinical evidence supports the existence of 
these clusters, but these approaches do not explore the possibility that different symptom 
clusters may occur over time. Furthermore, Cronbach’s alpha represents a limited condition 
for stability, as correlations do not fully capture the multiple symptom experience assessed by 
factor analysis. 
A limitation of cross-sectional analyses is that each analysis is independent and does 
not account for the influence of previous symptom experiences. One study investigated 
longitudinal patterns of rates of change in severity for 64 newly-diagnosed non-small-cell 
lung cancer  patients across 12 weeks of treatment [22]. Using growth curve analysis, four 
symptom clusters with different developmental trajectories were indicated [22].   
This review highlights, not only the variation in symptom cluster membership and 
symptom experiences over time, but that a core set of concurrent symptoms may occur 
consistently. Other symptoms may present at different stages of the disease/treatment 
trajectories. Due to individual variation, symptoms may not occur or be distressing at all 
assessments. This raises the question of whether a standard number of symptoms must re-
occur to constitute stability over time. Kirkova and Walsh [1] proposed symptom cluster 
stability over time may be established quantitatively (numerically) by the presence of at least 
75% of symptoms in the initial cluster, identified at subsequent times. This approach has not 
been investigated.  
 There is no optimal approach for symptom cluster identification over time. When 
symptom groupings are unknown, exploratory analyses are appropriate. Latent variable 
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methods include separate cross-sectional factor analyses for a group and longitudinal 
analyses of individual rates of change in symptom severity. The strength of a factor analysis 
model as a basis for symptom management strategies is the theoretical association of 
common underlying factors with multiple symptoms.  
 
Methods 
Participants 
Participants were outpatients diagnosed with cancer in the past 6 months, undergoing 
adjuvant treatment at two major oncology/hematology clinics in Brisbane in 2000-2001 and 
interviewed within 1 month (T1), at 6 months (T2), and 12 months (T3) after commencing 
chemotherapy. Ethical approval was obtained from the university and hospitals. All patients 
signed consent forms prior to participation. Details of the procedures, participants’ 
demographic and medical characteristics at all times, and a comparison of completers and 
non-completers due to attrition have been reported [23]. Participants not in the analysis at 12 
months due to attrition (death, refusal, unwell) and non-response were more likely to have 
Stage IV tumors and receive palliative treatment. 
 
Measures 
Physical symptoms were assessed on a clinician-modified Rotterdam Symptom 
Checklist (RSCL). Participants self-rated their perceived symptom distress in the past week 
from 1 (not at all) to 4 (very much).  Current treatment status (no, new, continuing) was 
assessed six-monthly.  
 
Statistical Analysis 
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This secondary data analysis was conducted using SPSS® version 15.0 (SPSS Inc. 
Chicago, IL). At each time, prevalence of distressing symptoms, distributions of severity 
ratings, concurrence, and treatment status were determined. Statistical relationships between 
symptoms were summarized by Pearson correlations. Data were not missing at random, so to 
avoid introducing further bias, missing values were not replaced by imputation.  
To maximize the use of available data, separate analyses were conducted at each time, 
in preference to using complete data at all times (n=121). Common factor analysis (CFA) 
with oblique rotation was implemented as an exploratory factor analysis best practice 
approach [24] also used by other researchers [11,14,13], although principal components 
analysis (PCA) with orthogonal rotation has been used [16,15,25,26,17]. To identify and 
interpret symptom clusters, CFA is appropriate, as common variance among symptoms is 
assessed, and it is assumed correlations between symptoms are due to a common cause. In 
PCA, total variance is assessed, so coefficients and communalities may be overestimated. 
Furthermore, there is no theoretical foundation to identify underlying factors. Oblique 
rotation allows correlated clusters, but would identify orthogonal clusters if they exist.  
As the data structure was unknown, CFAs were conducted at each time point at T2 
and T3 rather than confirmatory analyses at T2 and T3, based on the structure identified at 
T1. Principal axis factoring (PAF) was the method of extraction requiring no distributional 
assumptions and suitable for non-normal symptom data [27]. Initial communalities were 
estimated by squared multiple correlations (SMCs). In each analysis, the number of factors 
was decided from the scree plot [28] and Minimum Average Partial (MAP) procedure [29] 
using available syntax [30]. Following oblimin (oblique) rotation, analyses were repeated for 
varying numbers of factors until a simple structure [31] was evident in the pattern matrix, 
revealing symptoms more strongly associated with one factor than another. Symptoms were 
included in a cluster for structure coefficients (correlations between factors and symptoms) ≥ 
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.30, an arbitrarily chosen value indicating the factor explains about 10% of the variance in a 
symptom [24].  
As a basis for management strategies, symptoms could be associated with more than 
one factor, statistically and clinically. Final communality values indicate the percentage of 
the variance in each symptom accounted for by the common factors. Communalities from .20 
to .40 were classified as low [32], but if meaningful in the cluster, symptoms were retained. 
Clusters were finalized after clinical plausibility was reviewed, based on the literature and 
author interpretation. Qualitatively, stability of clusters over time was based on similar cluster 
composition likely to suggest a common cause. Quantitatively, the proportion of symptoms in 
clusters at T1 and replicated at T2 and T3 was compared against the proposed 75% 
replication rate for stability [1].  
 
Results 
Participants 
Of 219 participants, complete symptom data were reported by 202 at T1, 177 at T2, 
and 144 at T3. Median age of patients was 52 years (range: 18-79) and the majority were 
female (64%). Patients received one or more treatments, depending on their primary cancer 
site, treatment response, and disease progression. At T1, all patients underwent 
chemotherapy. At T2, new/continuing treatments for patients (77%) were mostly 
chemotherapy or radiotherapy. At T3, about half (48%) underwent chemotherapy mostly, or 
hormone therapy. Patient characteristics are summarized in Table 1. 
 
Symptom Distress 
The most prevalent distressing symptoms (score>1) at all times (Table 2) were fatigue 
(62%-65%) and daytime sleepiness (42%-50%). Other distressing symptoms were: hair loss 
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(41%), nausea (30%) and headache (30%) at T1; weakness (33%), headache (33%), 
numbness (32%), and dry mouth (31%) at T2; and muscle soreness (34%), dry mouth (31%), 
and joint pain (31%) at T3. Prevalence rates varied differentially over time; distress rates 
were consistent (e.g., fatigue), increased (e.g., muscle soreness), and decreased (e.g., loss of 
taste) over time, or increased at T2 and decreased at T3 (e.g., numbness). The median number 
of concurrent distressing symptoms was 7 (range: 0-32) at T1, 8 (range: 0-28) at T2, and 7 
(range: 0-26) at T3, reflecting a multiple symptom experience over time. 
 
Symptom Clusters at T1, T2, and T3 
From the scree plot and MAP, 5, 5, and 7 symptom clusters were suggested at T1, T2, 
and T3 respectively. Over time, five qualitatively consistent symptom clusters were 
characterized by a set of core symptoms (Tables 3-5): (1) Vasomotor (sweating, hot/cold 
spells and night sweats); (2) Oral-discomforts (difficulty swallowing, sore throat, sore 
mouth/pain swallowing); (3) Upper-gastrointestinal-discomforts/Aerodigestive (indigestion, 
heartburn and belching); (4) Gastrointestinal-toxicities (poor appetite, vomiting, nausea, 
shivering, stomach pain and trembling); and (5) Musculoskeletal-discomforts/lethargy 
(fatigue, sleepiness, muscle soreness and weakness). The Aerodigestive cluster differed from 
the Upper-gastrointestinal-discomforts clusters at T1 and T2 by the inclusion of chest pains 
and short of breath. An additional two clusters identified at T3 were Lethargy and 
Gastrointestinal/digestive symptoms in Table 6.  
Several symptoms were associated with multiple clusters. For example, at T2, poor 
appetite was associated with Oral-discomforts in Table 3, and Gastrointestinal-toxicities at all 
times in Table 4, with Lethargy and Gastrointestinal/digestive symptom clusters in Table 6. 
Weakness and fatigue were the most common symptoms across clusters, each associated with 
two clusters at T1, four clusters at T2, and five clusters at T3.  
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Replicating 75% of symptoms in clusters identified at T1 was achieved for the 
Vasomotor (75%) and Oral-discomforts (86%) clusters at T2, and the Musculoskeletal-
discomforts/lethargy (89%) cluster at T3. Otherwise, replication rates ranged from 43% to 
69% at T2, and from 38% to 54% at T3. Core symptoms were replicated and other symptoms 
transitioned in and out of clusters over time.  
 Overall, clusters comprised from 6 to 14 symptoms and inter-cluster correlations 
ranged from .05 to .30. Independent symptoms not in clusters, due to coefficients below .30 
and communalities below .20, included hair loss (T1), itchiness (T2), and heart pounding 
(T3). The factors best accounted for sore throat (T1), night sweats (T2) and fatigue (T3).  
 
Discussion 
Clinically, recognition of consistent symptom clusters is important to suggest 
intervention strategies in response to observed patterns in patients’ symptom experiences. 
However, few studies have investigated symptom clusters over time, or the complexity of 
symptom interrelationships for symptom management. This study assessed more symptoms 
than similar studies and is the first study to empirically identify symptom clusters for patients 
commencing chemotherapy, and 6 and 12 months later. Of the 42 symptoms analysed, only 
nausea, fatigue, pain, and appetite loss were common to other longitudinal studies reviewed.  
Compared to other studies, we used pattern coefficients to guide the decision on the 
number of clusters and structure coefficients to guide symptom inclusion in clusters [33,27]. 
Interpreting structure coefficients better reflects the clinical reality that symptoms could arise 
from different causal mechanisms, and as such, may be associated with different symptoms in 
each cluster. Our clusters comprised 6 to 14 symptoms, compared to clusters of 2 to 4 
symptoms in studies assessing fewer symptoms and interpreting pattern coefficients to 
identify symptoms uniquely associated with one factor. 
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Overall, the findings support other research that stable symptom clusters may exist, 
independent of treatment type and primary site [18,19,11]. Core sets of symptoms were 
identified consistently in five clusters over time; two additional clusters were determined at 
T3. All patients received chemotherapy at T1, 77% and 50% received treatment 
(predominantly chemotherapy) at T2 and T3 respectively, so the effects of treatment may be 
diluted over time. Specific treatment effects could not be determined, as the effects of 
sequential treatments may overlap (e.g., radiotherapy and chemotherapy). Nevertheless, the 
possibility remains that the identification of symptom clusters at T3 may be attributed to 
continuing treatments, particularly chemotherapy, or the effects of disease progression. 
Clusters at T3 comprised more symptoms, perhaps due to less variation in symptom 
distress or a shift in patient response  to symptoms experienced over a sustained period (i.e., 
less bothered). The resolution of some symptoms, as well as the cumulative or long-lasting 
effect of other symptoms associated with treatments, may account for the different symptom 
relationships over time, and changing causes.  
Alternative management strategies may be suggested for symptoms in multiple 
clusters. This highlights the advantage of our approach to interpret the complex 
interrelationships. For example, poor appetite at T2 was associated with Oral-discomforts and 
Gastrointestinal-toxicities, so appetite may improve if other symptoms (e.g., sore throat or 
vomiting) are relieved. Further investigation of the symptom clusters identified and their 
underlying causes is warranted.  
The stability of symptoms in clusters over time, such as sleepiness, fatigue, poor 
appetite, vomiting, and nausea in the Gastrointestinal-toxicities cluster, may suggest an 
underlying etiology of cytokine production, similar to the Sickness–behavior symptom 
clusters of pain, fatigue, insomnia, and appetite loss [19], fatigue, drowsiness, and insomnia 
[14], and nausea, vomiting, and decreased appetite  [11]. This finding supports the possibility 
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that a cluster of Sickness-behavior symptoms may exist independent of treatment type, 
primary cancer site, and stage of treatment.  
The variety of symptoms identified in clusters at different times supports the use of 
exploratory CFA in this study, as the data structure was unknown. Symptom clusters 
statistically-derived by CFA are more likely to suggest a common pathophysiology, not 
theoretically inherent in PCA [24,34]. In contrast, confirmatory factor analyses at T2 and T3, 
of the clusters identified at T1, would assess stability for that structure only, so were not 
implemented, although model modifications may be suggested in these analyses. Using 
Cronbach’s alpha for cluster identification also assumes the same cluster exists over time. 
Such clusters may exist, or the clusters could be a limited set of symptoms. Our 
Gastrointestinal-toxicities clusters at T1-T3 and our Lethargy cluster at T3 are similar to the 
cluster of fatigue, weakness, nausea, vomiting, appetite loss, weight loss, and altered taste 
confirmed over time using Cronbach’s alpha[20]. Cronbach’s alpha [12] is based on paired 
correlations, so this approach does not fully capture the multiple symptom experience 
assessed in CFA. Coefficient alpha represents a necessary, but not sufficient, condition for 
stability. 
Rather than assign cross-loading symptoms only to the most conceptually appropriate 
cluster [14], we allowed symptoms to indicate more than one cluster, for two reasons. Firstly, 
there may be no clear choice, conceptually. For example, based on structure coefficients 
ranging from .37 to .43, weakness was associated plausibly with five clusters at T3. Secondly, 
our intended application of the identified clusters was to consider intervention strategies, not 
to develop parsimonious symptom scales. Hence, recognizing that symptoms were associated 
across multiple clusters suggests different etiologies for these symptoms, and increased 
intervention opportunities based on different clusters. Although there is no correct 
interpretive approach for all contexts, interpreting structure coefficients reflects the clinical 
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reality in our study that symptoms could arise from different causal mechanisms, and as such 
were more likely to be associated with different symptoms across clusters. Pattern 
coefficients, the basis of cluster identification in other studies, may be useful to decrease 
cross-loadings and identify distinct factors. This may be important to measure and score 
symptom clusters to evaluate change in clusters over time.  
It is important to identify symptom clusters for a heterogeneous population, as this 
reflects the clinical setting. The disadvantage is statistical, requiring subgroup factor analyses 
to address potential confounding, which in this and many studies is not conducted due to the 
limited sample size. Participants were considered to be representative of outpatients 
undergoing adjuvant treatment that was predominantly chemotherapy, but the mixed cancer 
diagnoses and treatments of varying duration may have influenced the aggregations. We 
assumed the same cluster structure exists for symptoms experienced by patients with different 
personal and medical characteristics. This may be true: the sample was homogeneous for 
chemotherapy at T1, chemotherapy was the predominant treatment at T2 and T3, and many 
of the symptoms associated with radiotherapy and chemotherapy are similar, but differ in 
their severity [35,36]. 
In this study, all 42 symptoms were analysed, as exclusion of low prevalence 
symptoms may ignore symptoms important to the few who experience them. Factor analysis 
does not require exclusion of variables other than outliers, although exclusion focuses the 
analysis on the most prevalent symptoms [13,11] and may address lack of variation in 
response [14]. However, if a symptom (e.g., deafness) is not a stable member over time, it 
may not belong in the cluster, or more likely, it is correlated with other symptoms not 
assessed (e.g., neurological). Clearly, deafness should not be ignored. 
Determining stability based on 75% replication of T1 symptoms was achieved only 
for a few clusters. This replication rate may be higher for clusters identified from pattern 
   
14 
 
coefficients, as typically clusters would have fewer symptoms. Qualitatively, a symptom 
cluster appears stable if core symptoms are identified consistently over time. The percentage 
of symptoms replicated (i.e., quantitative determination) may not be important as individuals 
are unlikely to always experience all symptoms in a cluster.  
The present study has several limitations. In this secondary analysis, there was no 
control over the sample and symptom assessment (i.e., instrument and timing). There was no 
assessment prior to treatment, so symptom prevalence before treatment is unknown. Only 
physical symptoms were assessed, although psychological symptoms are known to influence 
patients’ symptom experience [37], and cognitive symptoms (e.g., memory loss, lack of 
concentration) may follow adjuvant therapy [38]. Patients in poor health were lost to attrition. 
Hence, the symptom experience assessed in this study may be less variable and less 
distressing than in the complete cohort. Alternatively, analyses that make the most of 
longitudinal designs (e.g., linear mixed effects models) may capture this variation.  
  The advantage of symptom clusters identified by CFA is the assumption of a 
common cause, but the limitation is the restriction to cross-sectional analyses with no 
consideration of the correlations between earlier and current experiences, despite the 
evidence of shift response [39] and symptom burden [40]. Longitudinal analyses are 
necessary to properly evaluate change in symptom clusters over time. Confirmatory factor 
analyses may address longitudinal change in symptom clusters, but has not been utilized, due 
to the exploratory phase of this research. Latent growth curve modeling has the advantage of 
determining when individuals may expect the greatest impact from each symptom cluster in 
the course of treatment, and of identifying different patient subgroup experiences, but more 
time points, fewer symptoms, and large sample size are preferable. Validation of the 
symptom clusters identified, within patient subgroups and over time, is necessary to confirm 
their stability and confirm they are really ‘clusters’ in the clinical sense. 
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Conclusion 
Both consistency and variation over time were evident in the symptom clusters 
identified at 6-monthly intervals after chemotherapy commenced for outpatients with mixed 
diagnoses. Stability is a necessary attribute of symptom clusters, but definitional clarification 
is required. We propose a core set of concurrent symptoms identifies each symptom cluster, 
signifying a common cause. Additional related symptoms may be included over time. 
Knowing which symptoms cluster is essential for clinical practice, to identify interventions 
for improved symptom management and patient outcomes, or if there is change, to tailor 
treatments to the change expected. Comprehensive symptom checklists are important in this 
exploratory phase, as shorter instruments result in limited symptom clusters and may not 
adequately reflect patients’ full symptom experience. Further longitudinal investigation is 
required to identify symptom clusters and the underlying causes (e.g., latent growth curves to 
identify symptom trajectories and influential factors). 
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Table 1 Baseline patient characteristics (N=219) 
 
Characteristic   
Age in years  
  Median (Range) 
 
 
52 (18-79) 
 
 n % 
Gender 
  Male 
  Female 
 
 
79 
 
140 
 
 
36.1 
 
63.9 
Primary cancer site   
   Breast 
   Gastrointestinal-colorectal 
   Hematological malignancies 
   Genitalia-urinary-reproductive 
   Respiratory-lung 
   Head-neck     
   Soft tissue, skin, brain, CNSa  
   Unknown 
63 
 
47 
 
46 
 
31 
 
15 
 
7 
 
7 
 
3 
28.8 
21.5 
21.0 
14.2 
6.8 
3.2 
3.2 
1.4 
Tumor stage  
    Stage I 
    Stage II 
    Stage III 
    Stage IV 
    Unknown/missing 
 
19 
62 
55 
24 
13 
 
9.0 
28.3 
25.1 
11.0 
5.9 
aCNS central nervous system 
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Table 2  Prevalencea of patient symptom distress over time   
 
Symptom 
< 1 month after 
commencing 
chemotherapy 
(N=202) 
6 months after 
commencing 
chemotherapy 
(N=177) 
12 months after 
commencing 
chemotherapy 
(N=144) 
 n % n % n % 
Fatigue 131 64.9 113 63.9 89 61.8 
Sleepy during day 85 42.1 89 50.3 70 48.6 
Loss of hair 83 41.1 28 15.8 6 4.2 
Nausea 61 30.2 43 24.3 25 17.4 
Headache 58 28.7 58 32.8 40 27.8 
Dry mouth 56 27.7 55 31.1 44 30.6 
Constipation 51 25.2 33 18.6 17 11.8 
Belching 40 24.8 31 17.5 23 16.0 
Pains in lower back 48 24.8 45 23.4 39 27.1 
Sweating 49 24.3 49 27.7 43 29.9 
Weakness in body 46 22.8 59 33.3 40 27.8 
Hot/cold spells 45 22.3 43 24.3 42 29.2 
Muscle soreness 42 20.8 50 28.2 49 34.0 
Dizziness 42 20.8 38 21.5 34 23.6 
Bad taste in mouth 41 20.3 38 21.5 16 9.7 
Loss of taste 41 20.3 19 16.4 11 7.6 
Diarrhea 40 19.8 45 25.4 26 18.1 
Itchiness 40 19.8 34 19.2 29 20.1 
Stomach pain 39 19.7 44 24.9 33 22.9 
Cough 37 18.3 51 28.8 34 23.6 
Night sweats 36 17.8 40 22.6 29 20.1 
Poor Appetite 37 17.3 35 19.8 21 14.6 
Indigestion 34 16.8 30 16.9 16 11.1 
Weight gain 31 15.3 50 28.2 33 22.9 
Numbness/tingling 31 15.3 56 31.6 29 20.1 
Sore mouth/pain swallowing 31 15.3 17 9.6 8 5.6 
Short of breath 31 15.3 40 24.9 40 27.8 
Sore throat 29 14.4 23 13.0 16 11.1 
Joint pain 27 13.4 46 26.0 42 29.2 
Trembling 27 13.4 11 6.2 13 9.0 
Rash 24 11.9 25 14.1 11 7.6 
Heartburn 24 11.9 23 13.0 10 6.9 
Low abdominal pain 24 11.9 25 14.1 20 13.9 
Heavy feelings arms/legs 21 10.4 40 22.6 27 18.7 
Muscle cramps 21 10.4 29 16.4 27 18.7 
Generalised pain 20 9.9 28 15.8 21 14.6 
Chest pains 30 9.9 20 11.3 19 13.2 
Shivering 19 9.4 7 4.0 7 4.9 
Heart pounding 16 7.9 10 5.6 12 8.3 
Vomiting 15 7.4 11 6.2 7 4.9 
Difficulty swallowing 13 6.4 12 6.8 7 4.9 
Deafness 8 4.0 14 7.9 15 10.4 
a Percentage of patients with distress score >1 on RSCL 
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Table 3 Vasomotor and Oral-discomforts symptom clusters identified over time, after 
participants commenced chemotherapy  
Vasomotor symptom clusters 
< 1 month 6 months 12 months 
 (α= .73) SC  (α= .84) SC  (α= .85) SC 
headache 0.62 headache 0.32   
sweating 0.60 sweating 0.72 sweating 0.87 
hot/cold spells 0.58 hot/cold spells 0.72 hot/cold spells 0.77 
night sweats 0.53 night sweats 0.75 night sweats 0.72 
dizziness 0.52 dizziness 0.41   
numbness/ tingling 0.37 numbness/ tingling 0.42   
chest pains 0.42     
heart pounding 
/palpitations 
0.35 
 
 
 
 
  muscle soreness 0.60 muscle soreness 0.33 
  joint pain 0.52 joint pain 0.33 
  generalised pain 0.52 generalised pain 0.34 
  weakness 0.44 weakness 0.40 
  fatigue 0.42 fatigue 0.43 
  lower back pains 0.38   
 
 
 
 heavy feelings 
arms/legs 
0.35 
    weight gain 0.34 
  dry mouth 0.30   
    sleepy during day 0.31 
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    Table 3 (cont). 
 
Oral-discomforts symptom clusters 
< 1 month 6 monthsa 12 monthsb 
(α= .72) SC (α= .80) SC (α= .73) SC 
sore throat 0.75 sore throat 0.55 sore throat 0.77 
sore mouth 
/pain swallowing 
0.71 sore mouth 
/pain swallowing 
0.46 sore mouth 
/pain swallowing 
0.67 
difficulty 
swallowing 
0.63 difficulty 
swallowing 
0.56 difficulty 
swallowing 
0.72 
bad taste 0.44 bad taste 0.38   
loss of taste 0.42 loss of taste 0.44   
dry mouth 0.41 dry mouth 0.41   
deafness 0.35     
  cough 0.56 cough 0.57 
  weakness in body 0.54 weakness in body 0.37 
  short of breath 0.33 short of breath 0.33 
  fatigue 0.33 fatigue 0.33 
  poor appetite 0.54   
  belching 0.33       
alower back pains excluded (lack of plausibility), brash excluded (lack of plausibility) 
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Table 4 Gastrointestinal-related symptom clusters identified over time, after commencing 
chemotherapy 
Upper-gastrointestinal-discomforts symptom clusters Aerodigestive symptom 
clusters 
< 1 month 6 months 12 monthsa 
(α= .68) SC  (α= .65) SC (α= .71) SC 
indigestion 0.66 indigestion 0.58 indigestion 0.49 
heartburn 0.59 heartburn 0.46 heartburn 0.62 
belching 0.59 belching 0.49 belching 0.36 
stomach pain  0.57     
nausea  0.31   nausea 0.30 
low abdominal pain 0.31     
constipation 0.30     
  heart pounding  0.38   
    chest pains 0.43 
  shivering 0.37 shivering 0.33 
  night sweats 0.34   
    short of breath 0.45 
    sleepy in day 0.34 
        deafness     0.52 
Gastrointestinal-toxicities symptom clusters 
< 1 month 6 months 12 months 
(α= .78) SC (α= .79) SC (α= .80) SC 
poor appetite  0.54 poor appetite 0.47 poor appetite 0.32 
vomiting  0.51 vomiting 0.50 vomiting 0.47 
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Table 4 (cont). 
 
nausea  0.50 nausea 0.53 nausea 0.44 
shivering  0.42 shivering 0.46 shivering 0.60 
trembling  0.38 trembling 0.54 trembling 0.52 
low abdominal pain  0.38 low abdominal pain 0.47   
stomach pain  0.37 stomach pain 0.64 stomach pain 0.37 
diarrhea  0.35 diarrhea 0.40 diarrhea 0.45 
belching  0.35     
loss of taste 0.31   loss of taste 0.40 
    bad taste 0.66 
    dry mouth 0.33 
sleepiness 0.67 sleepiness  0.39   
fatigue 0.50 fatigue 0.39   
weakness   0.33 weakness 0.37   
  lower back pains 0.31   
    dizziness 0.38 
 
 
     
 heavy feelings 
arms/legs 
0.38 
      SC = structure coefficient.  
      aRash, itchiness excluded (lack of plausibility) 
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Table 5 Musculoskeletal-discomforts/lethargy symptom clusters identified over time, 
after commencing chemotherapy  
Musculoskeletal-discomforts/lethargy symptom clusters 
< 1 montha 6 monthsa 12 months 
(α= .73) SC (α= .79) SC (α= .84) SC 
weakness  0.69 weakness  -0.51 weakness    -.41 
muscle soreness  0.66 muscle soreness -0.34 muscle soreness -.64 
joint pain 0.48   joint pain -.65 
heavy feelings in 
arms/legs  
0.47 heavy feelings in 
arms/legs 
-0.65 heavy feelings in 
arms/legs 
-.65 
generalised pain  0.39   generalised pain -.55 
lower back pains  0.34   lower back pains -.53 
fatigue  0.41 fatigue  -0.65 fatigue -.45 
sleepy during day 0.35 sleepy during day  -0.61 sleepy during day  -.35 
deafness 0.33     
  dizziness -0.46 dizziness -.36 
  dry mouth -0.34   
  short of breath -0.30   
  shivering -0.30   
 
 heart pounding/ 
palpitations 
-0.43 heart pounding/ 
palpitations 
-.30 
  muscle cramps -0.37 muscle cramps -.56 
  headache -0.36 headache -.33 
    trembling -.31 
    night sweats  -.30 
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     Table 5 (cont). 
 
        weight gain     -.41 
      SC = structure coefficient  
        aItchiness excluded (lack of plausibility)  
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Table 6 Symptom clusters only identified at 12 months after commencing chemotherapy 
Lethargya 
(α = .85) 
 
 
SC 
Gastrointestinal/ 
digestive symptoms 
(α = .86) 
 
 
SC 
fatigue 0.58 fatigue  0.41 
weakness in body 0.43 weakness in body  0.39 
sleepy during day 0.54   
headache 0.45   
dizziness 0.42   
short of breath 0.42   
lower back pains  0.30 lower back pains  0.30 
loss of taste 0.56 loss of taste 0.31 
poor appetite 0.46 poor appetite  0.60 
constipation 0.36 constipation  0.50 
nausea  0.37 nausea  0.42 
dry mouth 0.33 dry mouth 0.34 
  generalised pain  0.58 
  low abdominal pain 0.75 
  stomach pain  0.78 
  indigestion  0.45 
  belching  0.43 
SC = structure coefficient  
aHair loss excluded (lack of plausibility)  
 
 
 
